In this article, we will take a look at the best fundamentally strong penny stocks to buy according to analysts.Penny stocks often have a reputation for being volatile and risky, but some of these stocks are actually supported by strong fundamentals and growth potential. For investors willing to take the risk, such stocks represent a combination of valuation appeal and improving quality.The broader macro backdrop remains an important consideration in the current market. In his December 18 article “Economic ...

Core Insights - The Federal Reserve is expected to cut interest rates again, contributing to a strong earnings outlook for 2026, which may encourage investors to add to their portfolios in December and early 2026 [1] Group 1: Investment Opportunities - Investors are encouraged to seek out cheap stocks trading under $10 that have strong Zacks Ranks, indicating improving earnings outlooks [2] - Stocks priced between $5 and $10 are generally considered less risky than penny stocks, making them more appealing to investors [5] - A screening process is outlined to identify potential winning stocks under $10, focusing on Zacks Rank, broker ratings, analyst coverage, earnings estimate revisions, price, and trading volume [6][8] Group 2: Specific Stock Highlight - Amicus Therapeutics (FOLD) is highlighted as a promising biotech stock, with a focus on developing medicines for rare diseases [9] - The company reported a 17% revenue growth in Q3 and achieved GAAP profitability, with projections of 19% revenue growth in 2025 and 2026, reaching $745.4 million [10] - FOLD is expected to expand its adjusted earnings by 50% in FY25 and 87% in FY26, with a current Zacks Rank of 1 (Strong Buy) [11]

Core Viewpoint - Penny stocks are seen as high-risk, high-reward investments, with growing interest in select stocks as 2026 approaches, particularly those in fast-moving sectors [1][2] Group 1: Plug Power (NASDAQ: PLUG) - Plug Power is a hydrogen and clean-energy firm showing signs of potential turnaround after years of volatility, with a new liquefaction plant in Louisiana increasing U.S. hydrogen production capacity to approximately 40 tons per day [3][4] - The Georgia facility achieved a record production of 300 metric tons of liquid hydrogen in a single month, marking the highest output in the U.S. hydrogen sector [4] - The company raised $280 million in March 2025 and secured $399.4 million in net proceeds from a convertible-note financing in November 2025, which helped retire a first-lien loan and support expansion plans [4] - Despite ongoing losses and dilution risks, improving production metrics and rising hydrogen demand position Plug Power for potential re-rating if execution improves, with shares down nearly 10% year-to-date, closing at $2.11, up 9% [5] Group 2: Mobile-health Network Solutions (NASDAQ: MNDR) - Mobile-health Network Solutions is transitioning from physical clinics to an AI-driven virtual-care platform, reporting $7.7 million in revenue for the fiscal year ending June 30, 2025, a 45.3% decline due to exiting the clinic business [8][9] - The shift to an asset-light model significantly improved its cost structure, narrowing net loss from $15.6 million in FY2024 to $3.4 million in FY2025 [9] - In late November 2025, MNDR announced plans to acquire two AI-optimized data centers in Malaysia, with a potential share issuance of up to 3 million Class A shares valued at up to $120 million based on an agreed share price of $40 [10] - MNDR's stock dropped nearly 85% year-to-date but ended the last session up over 22% at $2.26 [11] Group 3: Common Traits - Both Plug Power and Mobile-health Network Solutions are undergoing measurable transformations supported by concrete progress in production, financial improvements, and strategic expansion [13]

Core Insights - The article discusses the current investment landscape for penny stocks, emphasizing that their performance is influenced more by market psychology than macroeconomic conditions [1] - Small-cap stocks are gaining momentum, particularly after strong third-quarter earnings, making them more attractive compared to large-cap stocks [2] - Several catalysts are driving interest in small-cap stocks, including M&A activity, biotech developments, and opportunities in sectors linked to AI [3] Small-Cap Stock Performance - The Russell 2000 index has increased by 21.60% over the past six months, although it has experienced four consecutive weeks of decline recently [4] Methodology for Stock Selection - The list of 12 hot penny stocks was compiled based on stocks priced under $5, with over 50% returns in the last three months and an upside potential exceeding 20% as of November 24, 2025 [6] - Hedge fund sentiment was also considered, utilizing data from Insider Monkey's hedge fund database tracking 983 hedge funds as of Q2 2025 [7] Individual Stock Highlights - **Shattuck Labs, Inc. (NASDAQ:STTK)**: - 3-month performance of 102.21% with an average upside potential of 45.63% [9] - The company has a cash balance of $86.10 million and reported a net loss of $10.1 million for Q3 2025 [10][11] - **Erasca, Inc. (NASDAQ:ERAS)**: - 3-month performance of 93.08% with an average upside potential of 73.01% [13] - The company reported a net loss of $30.6 million for Q3 2025 but has a solid cash position of $362.4 million [15][17] - **CytomX Therapeutics, Inc. (NASDAQ:CTMX)**: - 3-month performance of 107.50% with an average upside potential of 78.09% [18] - The company reported a revenue decline to $6 million for Q3 2025 but maintains a cash balance of $143.6 million [20][21]

Market Overview - The equity markets are facing potential declines after a record-high performance, with concerns about valuations and profit-taking [1][2] - Analysts predict a possible market pullback of up to 9%, with technical factors indicating downside risks [2][3] - The US Federal Reserve's interest rate cuts are expected to stimulate economic growth, benefiting small-cap and penny stocks [3][4] Small-Cap Performance - Historically, small-cap companies have outperformed large-cap companies during central bank easing cycles, with an average return of 35% for the Russell 2000 compared to 23% for the SPX in the year following rate cuts [4] - A dovish Federal Reserve is seen as a positive indicator for small-cap performance [5] Fastest Growing Penny Stocks - A list of the fastest-growing penny stocks has been compiled, focusing on companies trading under $5 with over 100% sales growth in the past year and 50% growth over three years [8] - Stocks were selected based on their upside potential of more than 30% and popularity among elite hedge funds [9] DeFi Technologies Inc. (NASDAQ:DEFT) - DeFi Technologies has shown significant sales growth with a 3-year sales growth of 1181.92% and a year-over-year growth of 138.94% [10] - The stock has an upside potential of 78.21% and is held by 9 hedge funds [10] - Despite a decline in revenues from $28.1 million to $22.5 million year-over-year, the company maintains a strong financial position with over $900 million in average assets under management [12][13] Ur-Energy Inc. (NYSE:URG) - Ur-Energy has a 3-year sales growth of 1181.92% and a year-over-year growth of 138.94%, with an upside potential of 80.21% and 22 hedge fund holders [15] - The company is positioned to benefit from increasing uranium demand, having secured off-take agreements with US nuclear power plants and projecting revenues of $27.2 million for 2025 [16][19] - Ur-Energy is ramping up production at its Lost Creek project and is set to start production at a second uranium mining project in Wyoming [17]

Group 1 - Robinhood Markets, Inc. (NASDAQ:HOOD) is recognized as one of the 15 Best Aggressive Growth Stocks to Buy currently [1] - Cantor Fitzgerald raised its price target for Robinhood from $130 to $155 while maintaining an Overweight rating [1] - The company reported a remarkable revenue growth of 100% year-over-year in Q3 2025, alongside record trading activity in equity and options [2] Group 2 - Total Platform Assets for Robinhood grew by 119% year-over-year, reaching $333 billion, supported by new deposits of $20.4 billion in Q3 [2] - Keefe, Bruyette & Woods also increased its price target for Robinhood from $121 to $135, maintaining a Market Perform rating [3] - The research firm adjusted its estimates for net interest revenues and transaction revenues due to stronger industry volume estimates, particularly in options and equities [3]

Group 1: Monster Beverage - In 1993, Monster Beverage, then known as Hansen's Natural, was a little-known juice and soda maker with stock trading around $0.05 per share [3] - A $1,000 investment at that time would have purchased approximately 20,000 shares, which are now worth about $1,291,800 as the stock trades at $64.59 per share [3] Group 2: Marvel Entertainment - Marvel faced significant challenges in the early 1990s, including a collapse in comic book sales and a bankruptcy filing in 1996 [4][6] - A $1,000 investment when Marvel's stock was around $1 would have bought about 1,000 shares, which turned into $30,000 in cash and 745 Disney shares after Disney's acquisition in 2009 [5] - The current value of those Disney shares, trading at $114 each, adds up to $84,194, leading to a total value of approximately $114,194 from the original investment [5] Group 3: Qualcomm - Qualcomm was relatively unknown in 1993, with its stock trading near $1 per share [7] - A $1,000 investment at that time would have bought about 1,000 shares, which are now valued at approximately $169,310 as Qualcomm trades at $169.31 per share [8]

Market Trends - New penny-stock listings for tiny overseas companies with dubious financial prospects proliferate on the Nasdaq exchange [1]

Core Insights - Coty Inc. (NYSE:COTY) is currently under investigation by Hagens Berman, a shareholder-rights law firm, to determine if the company misled investors regarding its growth and digital inventory strategy [2][3] - The company's stock experienced a significant decline of 21% on August 21, attributed to "retailer inventory destocking issues" impacting its Q4 and full-year results [3] - Berenberg has lowered its price target for Coty from $6.50 to $5.05, reflecting weaker sales growth expectations and reduced FY2026 EPS forecasts [4] Company Overview - Coty Inc. is one of the largest beauty companies globally, specializing in fragrances, color cosmetics, and skin and body care products [5] - The company is listed among the 10 cheapest penny stocks to buy currently [5] Market Context - The investigation and price target reduction come amid broader concerns about the company's sales growth and margin pressures due to tariff impacts and changes in compensation structures [4]

Core Insights - Protara Therapeutics is a clinical-stage biotech company focused on developing treatments for cancer and rare diseases, with its lead program TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [2][8] - TARA-002 utilizes a novel approach derived from a genetically distinct cell bank, functioning through dual mechanisms of directly killing tumor cells and stimulating an immune response [1][8] - The company is also advancing IV Choline Chloride for patients requiring parenteral nutrition, addressing a significant unmet need [10] TARA-002 Development - TARA-002 is currently being evaluated in a mid-stage study called ADVANCED-2 for NMIBC, showing promising early results with a 67% complete remission rate in BCG-unresponsive patients at six months [8][12] - In the Phase 2 STARBORN-1 trial for lymphatic malformations, two out of three pediatric patients achieved complete response after one injection, indicating a favorable safety profile [9][12] - Protara plans to deliver interim results for both trials in 1Q26 and 4Q25, respectively [8][9] Market Potential and Analyst Sentiment - Analysts project TARA-002 represents a potential market opportunity exceeding $500 million, with a strong buy consensus rating and a price target suggesting an 840% upside [12][13] - The average price target from analysts for TARA shares is $24.20, indicating a potential upside of approximately 659% [13] Financial Performance of Alpha Teknova - Alpha Teknova reported $10.3 million in revenue for 2Q25, a 7.3% year-over-year increase, with a reaffirmed full-year revenue guidance of $39-42 million [17] - The company is positioned to benefit from growth in the bioprocessing market, with expectations of over 20% revenue growth and 30%+ adjusted EBITDA margins in the long term [19][20] Analyst Ratings for Alpha Teknova - Alpha Teknova holds a strong buy consensus rating, with a price target of $12 indicating a potential one-year upside of approximately 159% [20]